Apellis PharmaceuticalsAPLS
APLS
About: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Employees: 710
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
34% more call options, than puts
Call options by funds: $26.6M | Put options by funds: $19.8M
20% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 75
0% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 6 (+0) [Q1 2025]
6% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 52
1.14% less ownership
Funds ownership: 101.87% [Q4 2024] → 100.73% (-1.14%) [Q1 2025]
3% less funds holding
Funds holding: 258 [Q4 2024] → 251 (-7) [Q1 2025]
32% less capital invested
Capital invested by funds: $4.04B [Q4 2024] → $2.77B (-$1.28B) [Q1 2025]
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$18
7%
downside
Avg. target
$32
63%
upside
High target
$52
167%
upside
11 analyst ratings
5 positive
45%
6 neutral
55%
0 negative
0%
Morgan Stanley Judah Frommer | 34%upside $26 | Equal-Weight Maintained | 2 Jul 2025 |
Wells Fargo Derek Archila | 49%upside $29 | Equal-Weight Maintained | 2 Jun 2025 |
Citigroup Yigal Nochomovitz | 111%upside $41 | Buy Maintained | 22 May 2025 |
Mizuho Graig Suvannavejh | 3%upside $20 | Neutral Maintained | 14 May 2025 |
Raymond James Ryan Deschner | 167%upside $52 | Outperform Downgraded | 9 May 2025 |
Financial journalist opinion
Based on 3 articles about APLS published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.
Neutral
PRNewsWire
1 week ago
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
STOCKHOLM , July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® (systemic pegcetacoplan) in exchange for $275 million upfront and up to $25 million in additional milestone payments dependent on regulatory approvals in the European Union for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). "We are pleased to continue our ongoing partnership with Apellis and share their strong belief in Aspaveli/EMPAVELI's potential to deliver significant long-term growth," said Guido Oelkers, Chief Executive Officer at Sobi.
Neutral
GlobeNewsWire
1 week ago
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
WALTHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced a capped royalty purchase agreement with Sobi® under which Apellis will receive up to $300 million in exchange for 90% of Apellis' future ex-U.S. royalties for Aspaveli® (systemic pegcetacoplan). Under the companies' 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties. Apellis retains exclusive commercialization rights for systemic pegcetacoplan in the United States, where the product is marketed as EMPAVELI®.
Positive
Zacks Investment Research
1 month ago
Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock?
Neutral
GlobeNewsWire
1 month ago
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress.
Neutral
GlobeNewsWire
1 month ago
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 10:40 a.m.
Positive
Seeking Alpha
1 month ago
Apellis Pharmaceuticals: Have Some Patience
Apellis Pharmaceuticals is a Buy due to the significant FCF potential of SYFOVRE® and EMPAVELI®, with SYFOVRE® projected to exceed $1bn in annual sales by 2028. SYFOVRE® has shown efficacy in slowing GA progression and saw a 122% YoY sales increase in 2024, despite initial rollout issues. EMPAVELI® offers moderate sales and is in trials for additional indications, promising incremental cash flows and contributing to EBITDA positivity by 2026.
Negative
Zacks Investment Research
2 months ago
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
Negative
The Motley Fool
2 months ago
Why Apellis Pharmaceuticals Wilted on Wednesday
A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (APLS -5.99%) stock in the middle of the trading week. Investors didn't take this development well, and they collectively pushed down Apellis by almost 6%, on a day when the S&P 500 (^GSPC 0.43%) closed in the black with a 0.4% gain.
Neutral
Seeking Alpha
2 months ago
Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Tracy Vineis – Vice President-Communications Cedric Francois – Co-Founder and Chief Executive Officer Tim Sullivan – Chief Financial Officer David Acheson – Executive Vice President-Commercial Caroline Baumal – Chief Medical Officer Conference Call Participants Jon Miller – Evercore Tazeen Ahmad – Bank of America Securities Anupam Rama – JPM Steve Seedhouse – Cantor Colleen Kusy – Baird Eliana Merle – UBS Annabel Samimy – Stifel Biren Amin – Piper Sandler Yigal Nochomovitz – Citigroup Douglas Tsao – H.C. Wainwright Lachlan Hanbury-Brown – William Blair Ryan Deschner – Raymond James Judah Frommer – Morgan Stanley Greg Harrison – Scotiabank Graig Suvannavejh – Mizuho Securities Lisa Walter – RBC Operator Hello, everyone.
Charts implemented using Lightweight Charts™